Lung Transplantation Outcomes and Peritransplant Sirolimus Use in Lymphangioleiomyomatosis.

ABSTRACT:

Background

With the introduction of sirolimus as medical therapy for lymphangioleiomyomatosis (LAM), an updated evaluation of LAM lung transplant (LT) outcomes and characterization of peritransplant sirolimus use is needed.

Methods

We identified adult LT recipients from 2005-2021 using the Scientific Registry of Transplant Recipients database and stratified by diagnosis (LAM vs other). Multivariable Cox regression was performed to calculate the adjusted hazard ratio for LAM vs other diagnoses. A pharmacy claims database was linked to provide sirolimus prescription information, and a subgroup analysis comparing outcomes with pre- vs posttransplant sirolimus use was performed.

Results

Of 32,337 recipients identified, 156 (0.5%) were diagnosed with LAM. Operative complic

SUBMITTER: Larson EL 

PROVIDER: S-EPMC11910819 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature